SAB Biotherapeutics (SABS)
(Delayed Data from NSDQ)
$4.00 USD
-0.05 (-1.11%)
Updated May 15, 2024 01:59 PM ET
After-Market: $4.00 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.00 USD
-0.05 (-1.11%)
Updated May 15, 2024 01:59 PM ET
After-Market: $4.00 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Zacks News
Here's Why SAB Biotherapeutics, Inc. (SABS) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
SAB Biotherapeutics, Inc. (SABS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 40% and 10.84%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Illumina (ILMN) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 300% and 2.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
SAB Biotherapeutics, Inc. (SABS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
SAB Biotherapeutics, Inc. (SABS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
SAB (SABS) Abandons COVID-19 Treatment Study, Stock Plummets
by Zacks Equity Research
Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.
SAB Biotherapeutics (SABS) Posts Data From COVID Treatment Study
by Zacks Equity Research
Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.